In pancreatic cancer cells, ginsenoside Rg3 upregulates the expression levels of long noncoding RNA cancer susceptibility candidate 2 (CASC2) and PTEN, leading to the suppression and programmed cell death of pancreatic cancer cells that are resistant to gemcitabine [641]. This evidence concerns the gene CASC2 and familial pancreatic carcinoma.